Ochs H R, Greenblatt D J, Eichelkraut W, LeDuc B W, Powers J F, Hahn N
Abteilung für Allgemeine Innere Medizin (Zentrum für Innere Medizin) und Experimentelle Chirurgie, University of Bonn, FRG.
Pharmacology. 1991;42(1):36-48. doi: 10.1159/000138766.
Domestic pigs received single intravenous and oral doses of lorazepam or clonazepam (1 mg/kg), benzodiazepine derivatives biotransformed by glucuronide conjugation and nitroreduction, respectively. Blood samples were simultaneously drawn from portal venous and systemic venous sampling sites during 8 h after dosage. After intravenous dosage with either drug, the area under the serum concentration curve (AUC) for the intact drug, as well as for the principal metabolites (lorazepam glucuronide and 7-aminoclonazepam, respectively), was nearly identical between portal and systemic serum. After oral dosage, absolute systemic availability (relative to intravenous administration) of both lorazepam and clonazepam was incomplete (mean values: 29 and 49%, respectively); however, metabolite levels were also correspondingly lower between oral and intravenous dosages. First-pass hepatic extraction also occurred for both drugs, with mean systemic/portal AUC ratios of 0.60 for lorazepam and 0.74 for clonazepam. Pretreatment with neomycin (1.0 g) had a minimal effect on portal or systemic AUC for intact clonazepam after oral dosage, but 7-aminoclonazepam concentrations were reduced by neomycin pretreatment. Thus incomplete absorption, together with first-pass hepatic biotransformation, appears to explain the incomplete systemic availability of orally administered lorazepam or clonazepam. Biotransformation within the gastrointestinal tract or during absorption through the gastrointestinal mucosa contributes minimally.
家猪分别静脉注射和口服单剂量的劳拉西泮或氯硝西泮(1毫克/千克),这两种苯二氮䓬衍生物分别通过葡萄糖醛酸结合和硝基还原进行生物转化。给药后8小时内,同时从门静脉和体静脉采样部位采集血样。静脉注射任何一种药物后,门静脉和体循环血清中完整药物以及主要代谢物(分别为劳拉西泮葡萄糖醛酸和7-氨基氯硝西泮)的血清浓度曲线下面积(AUC)几乎相同。口服给药后,劳拉西泮和氯硝西泮的绝对全身可用性(相对于静脉给药)均不完全(平均值分别为29%和49%);然而,口服和静脉给药之间代谢物水平也相应较低。两种药物均发生首过肝提取,劳拉西泮的平均全身/门静脉AUC比值为0.60,氯硝西泮为0.74。口服氯硝西泮后,新霉素(1.0克)预处理对门静脉或体循环中完整氯硝西泮的AUC影响极小,但新霉素预处理可降低7-氨基氯硝西泮的浓度。因此,吸收不完全以及首过肝生物转化似乎可以解释口服劳拉西泮或氯硝西泮全身可用性不完全的原因。胃肠道内或通过胃肠道黏膜吸收过程中的生物转化作用极小。